Table 1 Demographic, clinical, and therapy variables
Variables | All patients (n = 103) | Healthy controls |
|---|---|---|
Demographic variables | Â | Â |
   Female gender, percentage | 91 |  |
   Caucasian race, percentage | 77 |  |
   Age, years | 41 ± 13 |  |
Comorbidity | Â | Â |
   Diabetes mellitus, percentage | 4.9 |  |
Clinical and laboratory variables | Â | Â |
   Disease duration, years | 6.8 ± 4 |  |
   SLEDAI | 4.7 ± 4 |  |
   ECLAM | 3.1 ± 1.6 |  |
   SLICC/ACR damage index | 1.4 ± 1.9 |  |
   Previous biopsy proven lupus nephritis, percentage | 31.1 |  |
   Creatinine clearance <70 ml/minute, percentage | 18 |  |
   Proteinuria, percentage | 13.6 |  |
   Leucopoenia ever, percentage | 36.9 |  |
   Functional MBL serum level, median (range) μg/ml | 1.4 (0.04–7.60) | 1.1 (0.0–11.2) |
   Functional MBL serum level <0.05 μg/ml, percentage | 13 | 14 |
   MBL-induced C4 deposition on mannan, median (range) percentage | 71 (1.1–399) | 114 (3–494) |
   MBL-induced C4 deposition on mannan <10%, percentage | 21 | 16 |
   Functional activity of the MBL pathway, median (range) percentage | 16 (0.1–119) | 56 (0–133) |
   Functional activity of the MBL pathway <10%, percentage | 43 | 28 |
   C3 levels in serum, median (range) g/l | 0.86 (0.06–1.70) | (0.88–2.01) |
   C4 levels in serum, median (range) g/l | 0.13 (0.07–0.35) | 0.21 (0.11–0.61) |
Therapy variables | Â | Â |
   Oral corticosteroids |  |  |
Ever user, percentage | 81 | Â |
Current user, percentage | 52 | Â |
Duration of corticosteroid use in ever users, months | 63 ± 70 |  |
Actual prednisone dose if >0 mg/day, mg | 13 ± 12 |  |
   Intravenous methylprednisolone use ever, percentage | 15 |  |
   Hydroxychloroquine use ever, percentage | 87 |  |
   Azathioprine use ever, percentage | 37 |  |
   Methotrexate use ever, percentage | 14 |  |
   Cyclophosphamide (oral and/or intravenous) use ever, percentage | 13 |  |